Lycia Therapeutics
400 East Jamie Court,
Suite 200
South San Francisco
CA
94080
United States
Website: https://lyciatx.com/
Email: info@lyciatx.com
About Lycia Therapeutics
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
6 articles with Lycia Therapeutics
-
Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer
2/28/2022
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.
-
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
Money on the Move: September 8 – 14
9/15/2021
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies. -
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
9/9/2021
Lycia Therapeutics, Inc. today announced the completion of an oversubscribed $70 million Series B financing.
-
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.
-
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders
8/25/2021
Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.